Human Superantibodies to 3CLpro Inhibit Replication of SARS-CoV-2 across Variants

被引:6
|
作者
Glab-ampai, Kittirat [1 ]
Kaewchim, Kanasap [1 ,2 ]
Saenlom, Thanatsaran [1 ]
Thepsawat, Watayagorn [1 ]
Mahasongkram, Kodchakorn [1 ]
Sookrung, Nitat [1 ,3 ]
Chaicumpa, Wanpen [1 ]
Chulanetra, Monrat [1 ]
机构
[1] Mahidol Univ, Ctr Res Excellence Therapeut Proteins & Antibody, Dept Parasitol, Fac Med,Siriraj Hosp, Bangkok 10700, Thailand
[2] Mahidol Univ, Siriraj Hosp, Fac Med, Grad Program Immunol,Dept Immunol, Bangkok 10700, Thailand
[3] Mahidol Univ, Siriraj Hosp, Fac Med, Biomed Res Incubator Unit,Dept Res, Bangkok 10700, Thailand
关键词
SARS-CoV-2; major protease (3CL(pro)); human single-chain antibody variable fragments (HuscFvs); cell-penetrating antibody; superantibody; CORONAVIRUS 3C-LIKE PROTEASE; SARS-COV; HUMAN TRANSBODIES; HCV REPLICATION; ACTIVE-SITE; IDENTIFICATION; PROTEINASE; ANTIBODIES; DOMAIN;
D O I
10.3390/ijms23126587
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Broadly effective and safe anti-coronavirus agent is existentially needed. Major protease (3CL(pro)) is a highly conserved enzyme of betacoronaviruses. The enzyme plays pivotal role in the virus replication cycle. Thus, it is a good target of a broadly effective anti-Betacoronavirus agent. In this study, human single-chain antibodies (HuscFvs) of the SARS-CoV-2 3CL(pro) were generated using phage display technology. The 3CL(pro)-bound phages were used to infect Escherichia coli host for the production the 3CL(pro)-bound HuscFvs. Computerized simulation was used to guide the selection of the phage infected-E. coli clones that produced HuscFvs with the 3CL(pro) inhibitory potential. HuscFvs of three phage infected-E. coli clones were predicted to form contact interface with residues for 3CL(pro) catalytic activity, substrate binding, and homodimerization. These HuscFvs were linked to a cell-penetrating peptide to make them cell-penetrable, i.e., became superantibodies. The superantibodies blocked the 3CL(pro) activity in vitro, were not toxic to human cells, traversed across membrane of 3CL(pro)-expressing cells to co-localize with the intracellular 3CL(pro) and most of all, they inhibited replication of authentic SARS-CoV-2 Wuhan wild type and alpha, beta, .delta, and Omicron variants that were tested. The superantibodies should be investigated further towards clinical application as a safe and broadly effective anti-Betacoronavirus agent.
引用
收藏
页数:28
相关论文
共 50 条
  • [1] Prioritisation of Compounds for 3CLpro Inhibitor Development on SARS-CoV-2 Variants
    Jukic, Marko
    Skrlj, Blaz
    Tomsic, Gasper
    Plesko, Sebastian
    Podlipnik, Crtomir
    Bren, Urban
    MOLECULES, 2021, 26 (10):
  • [2] Geraniin as a potential inhibitor of SARS-CoV-2 3CLpro
    Yu, Wen-Di
    Jin, Qi-Ying
    Zeng, Mao-Sen
    Liu, Jin-Yuan
    Xu, Pei-Ping
    NATURAL PRODUCT RESEARCH, 2022, 36 (23) : 6060 - 6063
  • [3] Protocol for production and purification of SARS-CoV-2 3CLpro
    Mazzei, Luca
    Greene-Cramer, Rebecca
    Bafna, Khushboo
    Jovanovic, Aleksandar
    De Falco, Anna
    Acton, Thomas B.
    Royer, Catherine Ann
    Ciurli, Stefano
    Montelione, Gaetano T.
    STAR PROTOCOLS, 2023, 4 (02):
  • [4] The Repurposed Drugs Suramin and Quinacrine Cooperatively Inhibit SARS-CoV-2 3CLpro In Vitro
    Eberle, Raphael J.
    Olivier, Danilo S.
    Amaral, Marcos S.
    Gering, Ian
    Willbold, Dieter
    Arni, Raghuvir K.
    Coronado, Monika A.
    VIRUSES-BASEL, 2021, 13 (05):
  • [5] A Bioluminescent 3CLPro Activity Assay to Monitor SARS-CoV-2 Replication and Identify Inhibitors
    Mathieu, Cyrille
    Touret, Franck
    Jacquemin, Clemence
    Janin, Yves L.
    Nougairede, Antoine
    Brailly, Manon
    Mazelier, Magalie
    Decimo, Didier
    Vasseur, Virginie
    Hans, Aymeric
    Valle-Casuso, Jose-Carlos
    de Lamballerie, Xavier
    Horvat, Branka
    Andre, Patrice
    Si-Tahar, Mustapha
    Lotteau, Vincent
    Vidalain, Pierre-Olivier
    VIRUSES-BASEL, 2021, 13 (09):
  • [6] Discovery of 3CLpro inhibitor of SARS-CoV-2 main protease
    Kuang, Yi
    Ma, Xiaodong
    Shen, Wenjing
    Rao, Qingqing
    Yang, Shengxiang
    FUTURE SCIENCE OA, 2023, 9 (04):
  • [7] Flavonoids with inhibitory activity against SARS-CoV-2 3CLpro
    Jo, Seri
    Kim, Suwon
    Kim, Dae Yong
    Kim, Mi-Sun
    Shin, Dong Hae
    JOURNAL OF ENZYME INHIBITION AND MEDICINAL CHEMISTRY, 2020, 35 (01) : 1539 - 1544
  • [8] Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CLpro
    Ma, Ling
    Xie, Yongli
    Zhu, Mei
    Yi, Dongrong
    Zhao, Jianyuan
    Guo, Saisai
    Zhang, Yongxin
    Wang, Jing
    Li, Quanjie
    Wang, Yucheng
    Cen, Shan
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (24)
  • [9] An Updated and Focused Review on Heterocyclic Inhibitors for SARS-CoV and SARS-CoV-2 3CLpro
    Manaithiya, Ajay
    Alam, Ozair
    Mittal, Shruti
    Naim, Mohd. Javed
    Imran, Mohd
    Alshrari, Ahmed Subeh
    Sheikh, Aadil A. A.
    Khan, Imran A. A.
    MINI-REVIEWS IN MEDICINAL CHEMISTRY, 2023, 23 (05) : 576 - 632
  • [10] Structural and functional characterization of NEMO cleavage by SARS-CoV-2 3CLpro
    Mikhail A. Hameedi
    Erica T. Prates
    Michael R. Garvin
    Irimpan I. Mathews
    B. Kirtley Amos
    Omar Demerdash
    Mark Bechthold
    Mamta Iyer
    Simin Rahighi
    Daniel W. Kneller
    Andrey Kovalevsky
    Stephan Irle
    Van-Quan Vuong
    Julie C. Mitchell
    Audrey Labbe
    Stephanie Galanie
    Soichi Wakatsuki
    Daniel Jacobson
    Nature Communications, 13